Information Provided By:
Fly News Breaks for April 23, 2019
Apr 23, 2019 | 20:07 EDT
Piper Jaffray analyst Matt O'Brien kept his Overweight rating and $42 price target on Boston Scientific after its "long anticipated" FDA approval of Lotus Edge transcatheter aortic valve replacement, or TAVR, product. The analyst believes that with the combination of differentiated features and the "buzz at previous medical conferences" about the relaunch may accelerate the company's market share capture in the TAVR space. O'Brien calls today's news a "strong positive" for the stock given the "recent transvaginal surgical mesh notice and paclitaxel concerns."
News For BSX From the Last 2 Days
There are no results for your query BSX